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Introduction
Sphingolipids comprise a relatively small but vital fraction of the 
mammalian membrane lipids (Holthuis et al., 2001). Sphingo-
myelin (SM) carries a phosphocholine headgroup on a ceramide 
backbone and occurs in every mammalian cell, just like glucosyl-
ceramide (GlcCer). GlcCer serves as the basis for a highly poly-
morphic set of complex glycosphingolipids (GSLs). The unique 
physicochemical properties of sphingolipids allow different modes 
of interaction with their environment. Sphingolipids are con-
centrated at the cell surface and endocytotic membranes, where 
their bulk presence provides the membranes with chemical and 
mechanical stability. In addition, sphingolipids have the tendency 
to cluster with cholesterol in an environment of glycerolipids. 
The roles of sphingolipids in protein sorting, signaling, and mem-
brane deformation may therefore be explained by their ability to 
form lateral domains that specifi  cally include or exclude mem-
brane proteins. In addition, the broad diversity in glycosidic 
structure allows individual GSLs to interact specifi  cally with 
proteins, including viral and bacterial pathogens like Shiga and 
cholera toxin. The mode of action of sphingolipids in cellular 
processes depends on their concentration in the various sub-
cellular organelles and the trans-  bilayer and lateral distribution 
in those membranes. How cells sense and control the sphingo-
lipid concentration of their membranes is largely unknown, but 
the spatial organization of metabolism, action of translocators, 
and selectivity of transport are three important determinants that 
are intrinsically linked. Many but not all enzymes of sphingo-
lipid metabolism have been identifi  ed, some of them only very 
recently: the SM synthase (SMS) family (Huitema et al., 2004; 
Yamaoka et al., 2004) and two nonlyso  somal glucocerebrosidases 
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lycosphingolipids are controlled by the spatial 
organization of their metabolism and by trans  port 
speciﬁ   city. Using immunoelectron microscopy, 
we localize to the Golgi stack the glycosyltransferases that 
produce glucosylceramide (GlcCer), lactosylceramide 
(LacCer), and GM3. GlcCer is synthesized on the cytosolic 
side and must translocate across to the Golgi lumen for 
LacCer synthesis. However, only very little natural GlcCer 
translocates across the Golgi in vitro. As GlcCer reaches 
the cell surface when Golgi vesicular trafﬁ  cking is inhib-
ited, it must translocate across a post-Golgi membrane. 
Concanamycin, a vacuolar proton pump inhibitor, blocks 
translocation independently of multidrug transporters that 
are known to translocate short-chain GlcCer. Concanamycin 
did not reduce LacCer and GM3 synthesis. Thus, GlcCer 
destined for glycolipid synthesis follows a different path-
way and transports back into the endoplasmic reticulum 
(ER) via the late Golgi protein FAPP2. FAPP2 knockdown 
strongly reduces GM3 synthesis. Overall, we show that 
newly synthesized GlcCer enters two pathways: one toward 
the noncytosolic surface of a post-Golgi membrane and 
one via the ER toward the Golgi lumen LacCer synthase.
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(Yildiz et al., 2006; Boot et al., 2007; Hayashi et al., 2007). One 
contemporary challenge is to unravel how sphingolipid  metabolism 
is organized and controlled in the cellular context.
Ceramides are synthesized in the ER by various ceramide 
synthases (Pewzner-Jung et al., 2006). Some cell types express the 
galactosylceramide (GalCer) synthase (GalCS), which acts on the 
lumenal side of the ER (Sprong et al., 1998, 2003). However, all 
other synthetic enzymes of ceramide-containing lipids are located 
in the Golgi, with the exception of SMS2 at the plasma membrane 
(Huitema et al., 2004). Newly synthesized ceramides are trans-
ported from the ER to the Golgi, where they are converted by the 
GlcCer synthase (GCS) and SMS1. An important question is how 
cells regulate the cer  amide supply to these enzymes. A fi  rst clue 
has come from the fi  nding that the synthesis of SM but not GlcCer 
depended on ceramide transport to the trans-Golgi by ceramide 
transport protein (CERT; Hanada et al., 2003), a pathway that is 
regulated via phosphoinositides, sterols, and CERT phosphory-
lation (Perry and Ridgway, 2006). However, both SMS1 and GCS 
have been localized biochemically to the cis-medial Golgi, whereas 
GCS has also been assigned to pre-Golgi and trans-Golgi mem-
branes (Futerman et al., 1990; Jeckel et al., 1990, 1992; Futerman 
and Pagano, 1991; Kohyama-Koganeya et al., 2004). The current 
agreement is that GlcCer is synthesized on a cytosolic surface and 
translocates across the Golgi membrane for higher GSL synthesis 
in the late Golgi (Lannert et al., 1994, 1998).
However, the consensus picture is based on evidence ob-
tained before the recent identifi  cation of early enzymes in sphingo-
lipid metabolism and transport. In addition, the bulk of the lipid 
data has been collected using short-chain sphingolipid analogues 
by the lack of tools to study natural sphingolipids. Such short-chain 
analogues have much higher off rates from membranes and spon-
taneously exchange between membranes (Pagano et al., 1981). 
In addition, they are less well ordered in the membrane (Wang 
and Silvius, 2000). Therefore, we have addressed the following 
questions: (1) Where are the various enzymes situated along the 
Golgi stack? (2) Is natural GlcCer translocated across the Golgi 
membrane by multidrug transporters (van Meer et al., 2006)? 
(3) Is there a function for the glycolipid-binding proteins glyco-
lipid transfer protein (GLTP) in the cytosol (West et al., 2004) and 
FAPP2 on the trans-Golgi (Godi et al., 2004) in GSL   metabolism 
and transport (Godi et al., 2004; Malinina et al., 2004; Vieira 
et al., 2005, 2006)? Using a novel assay for the transmembrane 
translocation of natural GSLs, we report that GlcCer can reach 
the plasma membrane via nonvesicular transport and translocates 
to the cell surface. In contrast to the short-chain lipid analogues, 
natural GSLs are not translocated by the multidrug transporters 
but by a novel mechanism that, in turn, does not recognize short-
chain lipids. In addition, we have uncovered a pathway used by 
most GlcCer to reach the Golgi lumen. It involves transport from 
the Golgi to the ER by the glycolipid-binding protein FAPP2.
Results
Sphingolipid synthesis concentrates in the 
late Golgi and depends on CERT
Because the intra-Golgi localization of SMS1 and GCS is a 
matter of controversy (see Introduction), we fi  rst addressed their 
intracellular localization by immunofl  uorescence and immuno-
EM (IEM). Attempts to localize the endogenous enzymes of 
mammalian cells with specifi  c antibodies have failed so far, 
most likely because of their low expression levels. As an alterna-
tive, we ectopically expressed epitope-tagged constructs in HeLa 
cells and determined their cellular distribution using fl  uorescence 
microscopy (Fig. 1 and Fig. S1 A, available at http://www.jcb
.org/cgi/content/full/jcb.200704091/DC1) and EM (Fig. 2). 
In the confocal fl  uorescence microscope, both GCS and SMS1 
displayed a virtually identical staining pattern with endogenous 
GM130, a cis-Golgi marker (Nakamura et al., 1995), in tran-
siently transfected HeLa cells (Fig. 1). Neither SMS1 nor GCS 
was found in the nuclear envelope and ER. To determine the 
intra-Golgi localization of GCS and SMS1, HeLa cell lines 
stably expressing these enzymes were analyzed by IEM. Golgi 
stacks containing fi  ve cisternae were used for statistical analy-
sis, and endogenous GM130 was used as a cis-Golgi reference 
for every image. The intra-Golgi distribution of a protein was 
determined by counting all gold particles over a Golgi stack 
(n = 20 per protein), after which the number of gold particles 
found over a specifi  c cisterna was expressed as a percentage 
of total gold (Fig. 2 B). Indeed, GM130 was restricted mostly 
to the cis-most cisterna (81%), with only a little label in the 
next cisterna (Fig. 2, A and B). In contrast to GM130, labeling 
for GCS was found in all fi  ve cisternae but with higher con-
centrations in cisternae 3–5 (medial–trans). SMS1 was mostly 
present at the trans-side of the Golgi and clearly peaked in the 
fourth cisterna. Quantitation showed that GCS and SMS1 had 
a substantially differential distribution: almost 50% of GCS 
localized to the fi  rst three cisternae, whereas only 33% of SMS1 
was found there. Notably, SMS1 and GM130, which showed 
almost complete overlap by fl  uorescence microscopy, displayed 
different intra-Golgi distributions by IEM: GM130 was con-
centrated at the cis-side, and SMS1 was concentrated at the trans-
side of the Golgi.
Lactosylceramide (LacCer) synthesis not only depends on 
the presence of GlcCer but also on localization of the LacCer 
synthase (LCS) and the UDP-Gal transporter (UGT). LCS was 
found in all cisternae but peaked in cisternae 4 and 5. The loca-
tion of the UGT was more restricted to the medial–trans-Golgi 
and peaked in cisternae 3 and 4. LacCer is further converted to 
GM3 (sialyllactosylceramide) by the transfer of sialic acid from 
CMP–sialic acid. The GM3 synthase (GM3S) and the CMP–
sialic acid transporter (CST) localized exclusively to the Golgi 
stack, predominantly to the trans side (Fig. 2). Although a 100-fold 
overexpression of a Golgi-resident protein had no effect on 
the distribution of this protein within the HeLa Golgi (Rabouille 
et al., 1995), overexpression of a tagged version of a protein could 
lead to mislocalization. As one internal control, we therefore 
determined the localization of the UDP-GlcNAc transporter 
(NGT), which provides the medial-Golgi GlcNAc transferase with 
its substrate. It localized to the three medial cisternae with only 
little labeling in the fi  rst and last Golgi cisternae (Fig. 2, A and B). 
Collectively, the data indicate that the enzymes synthesizing 
LacCer and GM3 show a preferential medial–trans-localization, 
like SMS1, whereas the GCS is more evenly distributed over 
the Golgi stack.TRANSMEMBRANE TRANSLOCATION OF GLUCOSYLCERAMIDE • HALTER ET AL. 103
Translocation of short-chain but not 
natural GlcCer across the Golgi membrane
Because GlcCer is synthesized at the cytosolic aspect of the Golgi 
(see Introduction), we next addressed the question of whether 
GlcCer directly fl  ips to the lumenal side, where it can be used 
for complex GSL synthesis. Exogenously added N-6-NBD-
aminohexanoyl (C6-NBD)–GlcCer was readily converted to 
C6-NBD–LacCer in a postnuclear supernatant (PNS) of HeLa 
or CHO cells (Fig. 3; Burger et al., 1996; Lannert et al., 1998; 
Sprong et al., 2003). The translocation was 70% reduced by 
PSC833, an inhibitor of the ABC transporter ABCB1, a trans-
locator for C6-NBD–GlcCer (van Helvoort et al., 1996), and 
vanadate, which blocks the nucleotide-binding domain of ABC 
transporters. To test whether natural GlcCer translocates across 
the Golgi membrane, we monitored the conversion of exo-
genous [
3H]GlcCer to LacCer after insertion into the cytosolic 
leafl  et of membranes in the HeLa PNS by the small cytosolic 
GLTP (Fig. S2, A and B; available at http://www.jcb.org/
cgi/content/full/jcb.200704091/DC1). However, only a little 
[
3H]LacCer synthesis was observed unless the Golgi had been 
fused to the ER by brefeldin A (BFA) before the experiment, in 
which case the synthesis of [
3H]LacCer but not C6-NBD–LacCer 
increased fi  vefold (Fig. 3). The translocation of [
3H]GlcCer 
was not inhibited by PSC833 or indomethacin, inhibitors of 
Figure 1.  Cellular localization of enzymes in Golgi sphingolipid synthesis by confocal ﬂ  uorescence microscopy. HeLa cells were transiently transfected with 
the epitope-tagged enzymes (Table I). After 18 h, cells were ﬁ  xed, permeabilized, and labeled with rabbit antibodies against the HA or V5 epitopes and 
with mouse antibody against GM130, a cis-Golgi matrix protein. Cells were counterstained with FITC-labeled anti–rabbit (left) and Texas red–labeled anti–
mouse (GM130) antisera. Overlapping distributions appear as yellow in the merged images. After brefeldin A (BFA) treatment for 0.5 h, the glycosyl-
transferases were labeled with the speciﬁ  c antibodies followed by Texas red–labeled secondary antibodies. BFA fuses the Golgi stack to the ER. GCS, 
GlcCer synthase; LCS, LacCer synthase; GM3S, GM3 synthase; SMS1, SM synthase 1. For GCS, the transfected cells displayed 6.4× the activity of wild-
type cells. Bars, 10 μm.JCB • VOLUME 179 • NUMBER 1 • 2007  104
Figure 2.  Cellular localization of enzymes in Golgi sphingolipid synthesis by IEM. (A) HeLa cells stably transfected with the epitope-tagged enzymes (Table I) 
were double labeled for GM130 (10 nm protein A–gold; indicated by arrows) as a cis-Golgi marker and the speciﬁ  c enzyme (15 nm protein A–gold). 
Only a little labeling was present outside the Golgi in all cases, and this was similar to the signal found on untransfected cells. Clathrin coats, which are 
indicated by arrowheads, were often present on vesicles or tubules close to the TGN. CST, CMP–sialic acid transporter (SLC35A1); NGT, UDP-N-acetyl-
glucosamine transporter (SLC35A3); UGT, UDP-Gal transporter (SLC35A2). (B) For each enzyme, the gold labeling was quantiﬁ  ed in Golgi stacks that 
contained ﬁ  ve cisternae. The cisterna labeled with the cis-Golgi reference GM130 was denoted as 1. The number of gold particles per cisterna was 
expressed as a percentage of the total gold particles within that Golgi stack: mean percentage ± SEM (error bars; n = 20). Bars, 200 nm.TRANSMEMBRANE TRANSLOCATION OF GLUCOSYLCERAMIDE • HALTER ET AL. 105
the ABC transporters ABCB1 and ABCC1, nor by concana-
mycin A, a vacuolar proton pump inhibitor. ABCB1 and -C1 
translocate short-chain GlcCer (van Helvoort et al., 1996; van 
Meer et al., 2006), but the translocation of natural GlcCer 
across the ER–Golgi membrane was independent of these multi-
drug transporters.
Transport of simple but not complex GSLs 
continues with BFA
To see whether GlcCer could translocate toward the outer leafl  et 
of the plasma membrane, from where it can reach the site of 
LacCer synthesis (Trinchera et al., 1990b; Sprong et al., 2001), 
we labeled the newly synthesized lipids with [
14C]palmitate 
and, after various times, extracted the GSLs from the cell sur-
face by GLTP. Based on previous experience, the assay was op-
timized starting from a 1,000-fold higher GLTP concentration 
than that used for the delivery of GlcCer to PNS membranes 
in Fig. 3, and the standard assay conditions were defi  ned as 
45 min at 37°C with 1.5 mg/ml GLTP (Fig. S2, C and D). The addi-
tion of acceptor liposomes to the medium inhibited rather than 
stimulated GlcCer extraction by GLTP (Fig. S2 E), most likely 
because GLTP interacted with the liposomes even if they con-
tained no GSLs, thereby lowering the free GLTP concentration. 
Under these conditions, GLTP extracted 30–50% of the radio-
labeled GlcCer and 20–70% of the GM3 from various cell types in 
45 min but <0.5% of the SM and glycerophospholipids (Fig. 4, 
A–C). To check whether the phospholipid distribution across 
the membrane was affected by the extraction of the GSLs, expo-
sure on the cell surface of inner leafl  et phosphatidylserine was 
measured using FITC-labeled annexin V. No substantial annexin 
binding was observed in the GLTP-treated cells as compared 
with a positive control (Fig. 4 D). BFA induces fusion between 
the Golgi and ER and blocks vesicular traffi  c from the merged 
ER–Golgi to the plasma membrane. In mouse fi  broblast (MF) 
cells, BFA did not affect GM3 synthesis (Fig. S4, available 
at http://www.jcb.org/cgi/content/full/jcb.200704091/DC1) but 
fully blocked its transport (Fig. 4 A), which is in line with the 
relocation of GM3S to the ER and the absence of a nonvesicular 
pathway for GM3 transport (Warnock et al., 1994). The same 
was observed for GalCer sulfate (SGalCer) in the oligodendro-
cytic D6P2T cells (Fig. 4 C). In contrast, GlcCer transport 
persisted in the presence of BFA. GalCer (and galactosyldiacyl-
glycerol), which is synthesized in the ER lumen of CHO cells 
transfected with GalCS and in the ER lumen of D6P2T cells, 
behaved identically to GlcCer.
Transfer proteins GLTP and FAPP2
The fact that GlcCer and GM3 were synthesized in the same 
compartment in the presence of BFA (Fig. 1) and that GlcCer 
but not GM3 reached the cell surface under these conditions 
implied that GlcCer had reached the plasma membrane in the 
absence of vesicular traffi  c. Because natural GlcCer, in con-
trast to short-chain C6-NBD–GlcCer, does not readily exchange 
through the cytosol, we tested whether transport in the presence 
of BFA was mediated by a transfer protein. FAPP2, a protein 
that shares the glycolipid-binding domain with GLTP, has been 
found to be ubiquitously expressed (Godi et al., 2004). How-
ever, the knockdown of FAPP2 in MEB4 cells had no effect on 
the transport of newly synthesized GlcCer to the cell surface 
in the presence of BFA (Fig. 5 A). Likewise, a knockdown of 
GLTP in D6P2T cells did not reduce the transport of GlcCer 
(or GalCer; not depicted) to the plasma membrane in the presence 
of BFA (Fig. 5 B), indicating that transport from the merged 
ER–Golgi to the plasma membrane in the presence of BFA 
was not mediated by these proteins or that they are redundant. 
On the other hand, GLTP overexpression stimulated the trans-
port of GlcCer (and GalCer) in the presence of BFA twofold, 
showing that GLTP in vivo is able to fulfi  ll this function (Fig. 5 C). 
Unexpectedly, FAPP2 knockdown in MEB4 cells reduced 
transport to the plasma membrane by 30% in the absence of 
BFA, and the knockdown of GLTP in D6P2T cells reduced the 
transport of GlcCer (and also of GalCer; unpublished data) by 
30–50%, implying that >30–50% of the GlcCer that reached 
the cell under normal conditions had been transported by 
Figure 3.  Natural GlcCer translocates less efﬁ  ciently across 
the Golgi than across the ER membrane. PNSs were prepared 
from HeLa cells that had been (mock) treated with 1 μg/ml BFA. 
Equal volumes of PNS were incubated with or without 5 μM 
PSC833, 20 μM indomethacin (indometh), 1 mM vanadate, 
or 5 nM concanamycin A (ConcA) for 10 min at 37°C fol-
lowed by a 1-h incubation with 2 mM UDP-Gal and 1 μM 
C6-NBD–GlcCer complexed to BSA or 66 kBq/ml [
3H]GlcCer 
solubilized with recombinant GLTP. Each panel represents an 
independent set of experiments (n = 3). Lipids were extracted, 
analyzed, and expressed as the percentage of LacCer synthe-
sized in the control. Error bars represent SEM.JCB • VOLUME 179 • NUMBER 1 • 2007  106
Figure 4.  BFA completely blocks transport to the surface of complex glycolipids but not of GlcCer and GalCer. (A) 2D TLC radiogram of a typical experi-
ment in which MF cells pretreated ± 1 μg/ml BFA and labeled with [
14C]palmitate for 1.5 h were incubated for 45 min at 37°C with 1.5 mg/ml GLTP. 
The lipids were extracted from cells and medium, separated by 2D TLC, and analyzed by phosphorimaging (see Materials and methods). The marked 
lipids are (1) GlcCer, (2) GM3, (3) phosphatidylcholine, (4) phosphatidylethanolamine, (5) SM, and (6) precursor [
14C]palmitate. The origin is marked (o). 
First dimension, NH4OH solvent. (B) CHO-GalCS cells were labeled with [
14C]galactose for 1.5 h ±1 μg/ml BFA, and the transport of GlcCer, GalCer, 
and GM3 was assessed in a subsequent 45-min incubation with 1.5 mg/ml GLTP (medium), again ±BFA. Lipid numbering as in A, plus (7) GalCer and 
(8) galactosyldiacylglycerol. First dimension, NH4OH solvent; borate plates. (C) MF, CHO-GalCS, and D6P2T cells were treated as in A and B. Lipid 
transport as a percentage of that lipid found in the medium was calculated from at least three independent experiments for each lipid, each in triplicate. 
HeLa cells synthesized Gb3 instead of GM3, which could not be tested because its synthesis is interrupted by BFA (Fig. S4, available at http://www.jcb
.org/cgi/content/full/jcb.200704091/DC1). Error bars represent SEM. (D) MF cells were incubated with or without 1.5 mg/ml GLTP for 45 min at 37°C, 
ﬁ  xed, stained with FITC-conjugated annexin V, and analyzed by ﬂ  uorescence microscopy. As a positive control, MF cells were forced into apoptosis by 
overnight growth in serum-free medium, exposure to 200 J/m
2 UV light, and incubation in regular medium for 2 h at 37°C. The pictures were taken using 
identical settings. Bars, 10 μm.TRANSMEMBRANE TRANSLOCATION OF GLUCOSYLCERAMIDE • HALTER ET AL. 107
FAPP2 or GLTP followed by translocation across a post-Golgi 
membrane. We did not succeed in making a double knock-
down for FAPP2 and GLTP, possibly because this is a lethal 
combination. Transport of GM3 in MEB4 cells was not reduced 
by FAPP2 knockdown. As before, it was effectively blocked 
by BFA (unpublished data).
In contrast to C6-NBD–GlcCer, natural 
GlcCer is not translocated by ABCB1 
or -C1 but by a novel mechanism sensitive 
to concanamycin A
We have previously reported that a variety of short-chain GlcCer 
analogues, including C6-NBD–GlcCer, was transported to the 
cell surface by the multidrug transporters ABCB1 and -C1 (van 
Meer et al., 2006). Therefore, we addressed whether the trans-
port of natural GlcCer to the cell surface in the presence of 
BFA (Fig. 5) was mediated by these ABC transporters by using 
an MF cell line derived from the Abcb1a/Abcb1b/Abcc1 triple 
knockout (TKO) mouse (Wijnholds et al., 2000) vs. TKO cells 
stably transfected with human ABCB1 (MDR1). The transport 
of C6-NBD–GlcCer was strongly reduced in TKO cells (down 
to zero with BFA) and was partially restored by transfection 
with ABCB1 (Fig. 6 A), demonstrating that the translocation 
of C6-NBD–GlcCer across the plasma membrane of MF cells 
was fully the result of Abcb1 and Abcc1. In line with this, the 
C6-NBD–GlcCer translocation in MF cells was reduced by 
specifi  c inhibitors (PSC833 for Abcb1a/b) or general inhibitors 
(glibenclamide and vanadate) of ABC transporters (Fig. 6 B). 
In strong contrast, knockout of the multidrug transporters had 
no effect on the transport of natural GlcCer either in the ab-
sence or presence (unpublished data) of BFA. Transfection of 
the TKO cells with ABCB1 did not increase the translocation 
of natural GlcCer, nor was there a substantial effect of the 
various inhibitors, with one exception: concanamycin A, a spe-
cifi  c inhibitor of the vacuolar proton ATPase (Bowman et al., 
2006), essentially abolished the translocation of natural GlcCer 
without effect on C6-NBD–GlcCer (Fig. 6 B). Also, in the 
  absence of BFA, GlcCer transport to the cell surface was virtu-
ally abolished by concanamycin A (Fig. 6 C), which cannot be 
explained by an inhibition of vesicular traffi  c as indicated by 
the mild reduction in GM3 transport. Concanamycin had no 
effect on the synthesis of GM3 from newly synthesized GlcCer 
(unpublished data).
GlcCer readily reaches the lumen of the 
ER in vivo
Because concanamycin did not affect the rate of GM3 synthe-
sis, GlcCer destined for GM3 synthesis must have followed a 
different transport pathway independent of the post-Golgi trans-
location that was inhibited by concanamycin. Therefore, we 
tested the possibility that this GlcCer reached the site of LacCer 
synthesis in the lumen of the Golgi via the ER. To test whether 
GlcCer is present in the ER lumen, we introduced an enzyme 
into the ER lumen, the SGalCer synthase, that transfers a   sulfate 
from 3′-phosphoadenosine 5′-phosphosulfate (PAPS) to GalCer 
and GlcCer (Gasa et al., 1990) but that normally acts in the 
trans-Golgi in conjunction with the PAPS transporter (Farrer 
et al., 1995). A chimera (SGCS [chimeric protein consisting of 
Figure 5.  Effect of the expression levels of FAPP2 and GLTP on GSL transport to the cell surface. (A) MEB4 cells stably expressing RNAi plasmids 
against FAPP2 or lamin were preincubated with or without 1 μg/ml BFA for 0.5 h and labeled with [
14C]palmitic acid for 1.5 h. [
14C]GSLs were ex-
tracted from the cell surface during an additional 45-min incubation with 1.5 mg/ml GLTP in the medium. The lipids in the cells and media combined 
with the washes were analyzed and quantiﬁ  ed. Transport is expressed as the percentage of GlcCer recovered in the medium. (B and C) D6P2T cells 
stably expressing RNAi plasmids against GLTP or empty vector (B) or stably transfected with GLTP (C) were treated with BFA and labeled with 
[
14C]galactose, and transport of [
14C]GlcCer to the cell surface was measured as in A. Error bars represent SEM. (D) Western blot analysis from 
D6P2T clones expressing either RNAi plasmids (B) against GLTP and empty vector as control or pCDNA3.1 plasmids with GLTP-HA (C) using a rabbit 
antiserum against mouse GLTP. A background band at  40 kD (BG) and a blot against glyceraldehyde-3 phosphate dehydrogenase (GAPDH) were 
used as loading controls.JCB • VOLUME 179 • NUMBER 1 • 2007  108
an HA-tagged PAPS transporter and SGalCer synthase]) was 
constructed of the SGalCer synthase to an HA-tagged PAPS 
transporter. In MEB4 cells, SGCS showed a diffuse reticular 
staining and clear staining of the nuclear envelope. The patterns 
of SGCS and the cis-Golgi marker GM130 were mutually exclu-
sive (Fig. 7 A). In accordance with its location in the ER, SGCS 
remained sensitive to EndoH digestion (Fig. 7 B), implying the 
presence of high mannose N-glycans. The molecular mecha-
nism retaining the SGCS in the ER has remained unclear. It may 
contain a previously hidden ER retention signal, or maybe the 
complex is partially unfolded. When SGCS-transfected MEB4 
cells were labeled with [
35S]H2SO4, one major radioactive band 
appeared on TLC plates that ran faster than SGalCer (Fig. 7 C). 
When GlcCer and [
35S]PAPS were added to a PNS of MEB4 
cells transfected with the SGCS construct, a lipid product was 
made that ran above SGalCer. Synthesis depended on GlcCer, 
on PAPS, and on the transfection. A lipid with the same mobil-
ity on TLC was found in D6P2T cells. The band disappeared 
when the cells had been incubated with the GCS inhibitor 
N-butyldeoxygalactonojirimycin, identifying the unknown lipid 
as SGlcCer (Fig. 7 D and Fig. S3 A, available at http://www
.jcb.org/cgi/content/full/jcb.200704091/DC1). In addition, it was 
absent after a GCS knockdown but not an LCS knockdown 
(Fig. S3 B), which effi  ciently inhibited the synthesis of LacCer 
(not depicted). Finally, similar amounts of the [
35S]lipid were 
synthesized in SGCS-transfected CHO and mutant CHO-lec8 
cells (Fig. S3 C), which have threefold reduced LacCer levels 
(Sprong et al., 2003). Thus, GlcCer reached the lumen of the 
ER, where it was converted to SGlcCer by SGCS.
Role of FAPP2 in GlcCer transport 
to the ER
Selective GlcCer transport from the cytosolic surface of the 
Golgi back to the ER would be most easily explained by the 
activity of a cytosolic transfer protein followed by a transloca-
tion across the ER membrane. Therefore, we tested the in-
volvement of the glycolipid-binding protein FAPP2 in this 
pathway. When lamin and FAPP2 knockdown cells were trans-
fected with SGCS and labeled with [
35S]H2SO4, SGlcCer syn-
thesis in the FAPP2 knockdown cells was only 30% of that of 
the control (Fig. 7, D–F). In MEB4 cells, FAPP2 knockdown 
resulted in a twofold decrease in the synthesis of GM3 with 
a concomitant accumulation of GlcCer (Fig. 7 G). Similar 
results (Fig. 7 H) were obtained in MDCKII cells, in which 
FAPP2 expression was reduced by retrovirus-mediated RNAi 
(Vieira et al., 2005). GalCer levels in these cells were normal, 
indicating that ceramide levels in the ER were unaffected. 
FAPP2 specifi  cally affected the conversion of GlcCer to GM3 
via LacCer. These experiments show that FAPP2, which binds 
to the Golgi (Fig. S1 A) via PI4P (Godi et al., 2004), plays an 
important role in the transport of GlcCer to the sulfation site 
in the ER and to the site of LacCer and GM3 synthesis in the 
lumen of the Golgi. Concanamycin A did not affect GlcCer 
translocation across the ER membrane (Fig. 3), nor did it 
  affect GM3 synthesis from newly synthesized GlcCer (not 
depicted), showing that ER translocation occurred by a dif-
ferent mechanism and that the pathways of newly synthe-
sized GlcCer to the Golgi lumen and to the plasma membrane 
are independent.
Figure 6.  In contrast to C6-NBD–GlcCer, endogenous GlcCer 
is translocated by a mechanism that does not depend on multi-
drug transporters but is blocked by concanamycin A. (A) MF 
cells, TKO cells, an MF line with a triple knockout for the multi-
drug transporters Abcb1a, -b1b, and -c1, and TKO cells 
transfected with human ABCB1 were incubated with C6-NBD–
ceramide for 1 h or [
14C]palmitic acid for 1.5 h at 37°C. 
Labeled GlcCer was extracted from the cell surface by BSA and 
GLTP and quantitatively analyzed as described in Materials 
and methods. The same experiment was performed in the 
presence of BFA (not depicted). (B) MF cells were preincu-
bated with 1 μg/ml BFA ± 1 mM vanadate or 5 nM concana-
mycin A (ConcA) for 0.5 h at 37°C and incubated with 
C6-NBD–ceramide with BSA or [
14C]palmitate followed by GLTP, 
all in the presence of the inhibitors. 5 μM PSC833, 20 μM 
indomethacin, and 50 μM glibenclamide gave similar results 
to vanadate, both +BFA and –BFA. (C) MF cells (GlcCer and 
GM3) or D6P2T cells (GalCer) were preincubated with or 
without 1 μg/ml BFA and 5 nM concanamycin A for 0.5 h at 
37°C followed by incubations with [
14C]palmitate and GLTP, 
all in the presence of the inhibitors. Labeled GlcCer was 
extracted from the cell surface and quantiﬁ  ed as in A. Trans-
port was calculated as the percentage of the speciﬁ  c lipid that 
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Discussion
Until recently, sphingolipid assembly in the Golgi was thought 
to be organized according to the same simple linear model as 
glycoprotein processing (Fig. 8 A). Because it is not water 
soluble, ceramide synthesized in the ER would be transported 
by the secretory pathway to the cis-Golgi, where it would be 
converted to SM by SMS (Futerman et al., 1990; Jeckel et al., 
1990) and to GlcCer by GCS (Futerman and Pagano, 1991; 
Jeckel et al., 1992). Subsequently, GlcCer would encounter the 
enzymes of complex GSL synthesis in an ordered array along 
the Golgi stack (Trinchera et al., 1990a). The fi  nding that 
GlcCer is synthesized on the cytosolic surface but converted 
to LacCer in the lumen forced the questions whether and how 
Figure 7.  Transport of newly synthesized 
GlcCer to the lumen of the ER and its conver-
sion to GM3 are greatly reduced by knocking 
down FAPP2. (A) MEB4 cells were transiently 
transfected with a construct containing the 
sulfo-GalCS and the PAPS transporter (SGCS). 
After 18 h, the cells were ﬁ  xed and labeled 
with rabbit antibodies against the HA tag of 
SGCS and with mouse antibodies against 
GM130 followed by FITC (left) and Texas red 
secondary antibodies (right). (B) Cells (mock) 
transfected with SGCS were washed and lysed 
in 50 mM sodium citrate, pH 5.5, 2 mM EDTA, 
1 mM 2-mercaptoethanol, 0.1% SDS, and pro-
tease inhibitors. Half of the transfected sample 
received endoglycosidase H (EndoH), and 
all samples were incubated for 6 h at 30°C. 
Proteins were resolved on 7.5% SDS-PAGE fol-
lowed by Western blot detection with rabbit 
anti-HA antibodies. The housekeeping enzyme 
glyceraldehyde-3 phosphatase dehydroge-
nase  (GAPDH) served as a loading control. 
(C) MEB4 cells (mock) transfected with SGCS 
were incubated with 600 kBq [
35S]H2SO4/10
5 
cells. After 24 h, the lipids were extracted, 
separated by 1D TLC, and stained with iodine 
to visualize the bulk lipid phosphatidylcholine 
(PC) as a loading control. [
35S]lipids were 
visualized by phosphorimager screens. Western 
blot analysis with anti-HA antibodies was per-
formed on parallel dishes. (D) D6P2T cells were 
labeled overnight with [
35S]H2SO4 in the pres-
ence or absence of 40 μM of the GCS inhibi-
tor N-butyldeoxygalactonojirimycin (NB-DGJ), 
after which the lipids were analyzed by TLC 
and phosphorimaging. The more hydrophilic 
spot was most likely SLacCer. (E) Semiquantita-
tive RT-PCR on RNAs from MEB4 clones stably 
expressing RNAi plasmids against PCR frag-
ments of FAPP2 or lamin as a control to detect 
expression levels of FAPP2 and GAPDH as a 
control. (F) MEB4 cells stably expressing RNAi 
plasmids against FAPP2 or lamin were tran-
siently transfected with SGCS. After 18 h, cells 
were labeled with 3,600 kBq/ml [
35S]H2SO4 
for 8 h. The lipids were analyzed as in C. Par-
allel dishes had an equal expression of SGCS 
as checked by Western blotting against HA 
(not depicted). (G and H) MEB4 cells stably 
expressing RNAi plasmids against FAPP2 or 
lamin and MDCKII cells infected with empty 
virus (control) or with retrovirus-mediated RNAi 
against FAPP2 were labeled overnight with 
72 kBq/ml [
14C]galactose. Lipids were extracted 
and separated by 2D TLC, and radio  labeled lip-
ids were quantiﬁ   ed using a phosphorimager 
as described in Materials and methods. GSL, 
LacCer plus GM3 (MEB4) and a mix of com-
plex GSLs (MDCKII). Values are expressed as 
a percentage of total [
14C]lipids and are the 
mean of three experiments in triplicate. Error 
bars represent SEM. Bar, 10 μm.JCB • VOLUME 179 • NUMBER 1 • 2007  110
GlcCer crosses the Golgi membrane. This seemed solved by 
(1) the fi  nding that short-chain GlcCer analogues were able to 
cross the Golgi membrane (Lannert et al., 1994, 1998; Burger 
et al., 1996), (2) the identifi  cation of the multidrug transporters 
ABCB1 and -C1 as fl  oppases for these molecules (van Meer 
et al., 2006), and (3) a correlation between ABCB1 activity and 
complex GSL synthesis in living cells (De Rosa et al., 2004). 
However, the mechanism of SM synthesis is much more intri-
cate in that SMS receives its substrate via the cytosolic transfer 
protein CERT, which binds to ER and trans-Golgi and is regu-
lated at various levels via phosphorylation (Perry and Ridgway, 
2006; Fugmann et al., 2007; Kumagai et al., 2007).
Also, the synthesis and processing of GlcCer are more 
sophisticated than suspected (Fig. 8 B): (1) The GCS is con-
centrated in the trans-Golgi, not in the cis-Golgi, and its activ-
ity was inhibited more than twofold upon CERT knockdown. 
(2) In contrast to short-chain GlcCer, natural GlcCer did not fl  op 
effi  ciently across the Golgi membrane and was not a substrate 
for the multidrug transporter ABCB1. (3) Instead, newly syn-
thesized GlcCer reached the outside of the plasma membrane 
by a nonvesicular transport pathway and was translocated via a 
mechanism that was inhibited by concanamycin A, an inhibitor 
of the vacuolar ATPase, suggesting the involvement of a pro-
ton gradient. (4) Finally, most GlcCer reached the LCS in the 
Golgi lumen via the ER, with a role for the trans-Golgi glyco-
lipid-binding protein FAPP2 in shuttling GlcCer to the ER. This 
suggests that GlcCer may play a role in transport and sorting 
events at the ER. In addition, FAPP2 appears to regulate com-
plex GSL synthesis. The fi  nding that multiple pathways remove 
GlcCer from the cytosolic surface of the trans-Golgi suggests 
the possibility that GlcCer exerts a physiological function at 
that location.
Intra-Golgi organization of sphingolipid 
metabolism
The fi  nding that SM synthesis depends on the ER/trans-Golgi 
protein CERT for its ceramide supply suggested that the Golgi 
SMS is located in the trans-Golgi (Munro, 2003). Indeed, in HeLa 
cells, transfected SMS1 peaked in the fourth cisterna out of fi  ve 
(Fig. 2). Like Hanada et al. (2003), we observed that CERT 
knockdown also affected GCS synthesis from [
14C]serine, 
suggesting that [
14C]serine-derived ceramide is transported by 
CERT to the GCS in the trans-Golgi. However, these authors 
reported that GlcCer synthesis from [
3H]sphingosine was inde-
pendent of CERT, suggesting the existence of different ceramide 
pools and the preferential delivery of [
3H]sphingosine-derived 
ceramide by vesicular transport to cis–medial-Golgi GCS. 
A bimodal distribution of GCS and not SMS had been ob-
served before by cell fractionation (Futerman and Pagano, 1991; 
Jeckel et al., 1992) and is now corroborated by IEM of the trans-
fected GCS (Fig. 2). In contrast to the Drosophila melanogaster 
GCS (Kohyama-Koganeya et al., 2004), mammalian GCS 
was not in the ER. In the Golgi lumen, GlcCer is converted to 
LacCer, which, in most cells, is effi  ciently sialylated to GM3. 
The responsible enzymes, LCS and GM3S, have been assigned 
to the Golgi stack from the fact that they were still able to use 
newly synthesized GlcCer and LacCer after BFA treatment 
(van Meer, 1993). Cell fractionation assigned LCS to the 
trans-Golgi (Lannert et al., 1998) and GM3S to the cis-Golgi 
(Trinchera et al., 1990a), but GM3 synthesis was found highest 
in the trans-Golgi (Lannert et al., 1998; Allende et al., 2000). 
IEM located both enzymes and their nucleotide sugar trans-
porters to the trans-Golgi, peaking in cisterna 4 (Fig. 2), whereas 
NGT, the transporter for UDP-GlcNAc into the medial-Golgi, 
was more evenly distributed. Biochemical experiments have 
indicated that LCS and GM3S form a molecular complex (Giraudo 
and Maccioni, 2003), explaining the effi  cient utilization of 
LacCer by GM3S.
Translocation of GlcCer toward the 
noncytosolic surface
After synthesis, GlcCer must cross a membrane to reach the LCS 
in the Golgi lumen. When exogenous GlcCer analogues with 
shortened fatty tails were added to the Golgi, they were con-
verted to LacCer (Lannert et al., 1994, 1998; Burger et al., 1996), 
a process sensitive to the ABCB1 inhibitor PSC833 (Fig. 3). 
Figure 8.  Synthesis and transport of GSLs. (A) In the traditional model, 
ceramide moves to the cis-Golgi via vesicular transport and is converted to 
SM and GlcCer. GlcCer is further processed by transferases in the trans-
Golgi and TGN. (B) In the updated model, most ceramide is transported to 
the trans-Golgi by CERT, SM is produced in the lumen, and GlcCer is pro-
duced on the cytosolic surface. Most GlcCer is transported back to the ER 
via FAPP2, whereas another fraction reaches the cytosolic surface of the 
plasma membrane (or endosome), where it is translocated. The ER GlcCer 
(our assays do not strictly exclude the possibility that this is actually the 
cis-Golgi) enters the secretory pathway and is converted to LacCer and GM3 
in the trans-Golgi followed by further modiﬁ  cation in the TGN, depending 
on cell type. It remains unclear whether any GlcCer translocates directly 
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This suggests translocation by Abcb1, which also translocates 
newly synthesized C6-NBD–GlcCer across plasma membranes 
(Fig. 6, A and B; van Helvoort et al., 1996). In contrast, LacCer 
synthesis from natural GlcCer and translocation of newly syn-
thesized natural GlcCer across the plasma membrane were 
insensitive to PSC833 (Fig. 6 B). The latter translocation was 
sensitive to concanamycin, which suggests the involvement of 
a pH gradient. Because endosomal recycling still occurs under 
BFA (Lippincott-Schwartz et al., 1991), the translocation most 
likely occurred in the endosomes. How the low pH affects the 
transmembrane translocation of GlcCer is presently under 
investigation. Although concanamycin has some inhibitory effect 
on vesicular traffi  c (Fig. 6 C; Weisz, 2003), this does not ex-
plain the abolition of cell surface appearance under non-BFA 
conditions. One other potential translocator for GlcCer identi-
fi  ed in skin, ABCA12 (Lefevre et al., 2003), is not expressed in 
the cell lines used in this study.
The synthesis of LacCer from exogenous GlcCer in a PNS 
was greatly stimulated by BFA (Fig. 3). This suggests that 
GlcCer translocation across the trans-Golgi membrane was lim-
iting and that GlcCer effi  ciently fl  opped across the membrane 
of the ER–Golgi compartment, which, for 75%, consists of ER 
membrane (but is not the native ER membrane). Also, GalCer 
(and galactosyldiacylglycerol) appears to fl  ip across the ER–Golgi, 
but in the opposite direction: after synthesis on the lumenal side of 
the ER–Golgi in the presence of BFA, GalCer still reached the cell 
surface (Fig. 4, B and C). In the absence of   vesicular traffi  c 
from this organelle to the plasma membrane (as indicated by the 
lack of transport of GM3, SGalCer, and proteins; Fig. S5, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200704091/DC1), 
this transport must have involved translocation toward the 
cytosolic surface of the ER membrane, monomeric transport 
through the cytosol to the cytoplasmic side of the plasma mem-
brane, and outward translocation across the plasma membrane. 
There are several studies in the literature that have addressed 
lipid fl  ipping in the ER, and every lipid tested so far readily 
moves across the ER membrane in both directions by an energy-
independent mechanism (Papadopulos et al., 2007). We now fi  nd 
that this event is insensitive to inhibition of the multidrug trans-
porters (Fig. 3 B).
Cytosolic GlcCer transport and ER 
lipid rafts
Under BFA, when vesicular transport (measured as the appear-
ance of GM3 and SGalCer) was inhibited, natural GlcCer still 
reached the cell surface (Fig. 4 C). This shows that GlcCer 
synthesized in the ER–Golgi reached the cytosolic surface of 
the plasma membrane or an endosomal compartment (Warnock 
et al., 1994). Surprisingly, neither a knockdown of FAPP2 nor of 
GLTP, the two known cytosolic proteins with a glycolipid-binding 
domain, had an inhibitory effect, suggesting the involvement of 
a third protein or an independent mechanism like membrane con-
tact sites (Levine and Loewen, 2006). The knockdowns of these 
proteins did have an inhibitory effect in the absence of BFA, 
in which virtually all GlcCer arriving at the cell surface was 
translocated by the concanamycin-sensitive non-ER mechanism. 
This suggests that under normal conditions, GlcCer destined 
for the cell surface is transported by FAPP2 or GLTP from the 
  cytosolic surface of the Golgi to the post-Golgi membrane, where 
subsequent translocation occurs. The observation that the GlcCer 
transport remaining under BFA conditions was insensitive to 
FAPP2 or GLTP knockdown suggests that either there is a 
redundancy between these proteins or that, possibly, ultrastruc-
tural connections between the Golgi and post-Golgi membranes 
are involved that are broken by BFA (Lippincott-Schwartz et al., 
1991). After the translocation of GlcCer to the noncytoplasmic 
leafl  et of the post-Golgi membrane, part of this GlcCer might 
recycle to the Golgi, where it would be converted to LacCer 
(Trinchera et al., 1990b; Sprong et al., 2001), but this pathway may 
not be very active considering the lack of effect of concanamycin 
on GM3 synthesis (unpublished data).
The fi  nding that GlcCer reached the ER lumen as mea-
sured via an assay involving enzymatic modifi  cation suggested 
the involvement of one of the two known cytosolic GlcCer-
binding proteins. Because MEB4 cells have low levels of GLTP 
(not depicted), we knocked down FAPP2, a protein with a GLTP 
domain that is recruited to the trans-Golgi and TGN by PI4P 
(Fig. S1 A; Godi et al., 2004). The FAPP2 knockdown dramati-
cally reduced GlcCer transport to the ER lumen (Fig. 7 F). 
FAPP2 may transport GlcCer as a monomer via its GlcCer-
binding domain, which is analogous to ceramide transfer by 
CERT. Presently, we cannot exclude the possibility that FAPP2 
is involved in the generation of retrograde vesicles that, on their 
cytosolic surface, are enriched in GlcCer. FAPP2 knockdown 
inhibited GM3 synthesis by 50% (Fig. 7, G and H), suggesting 
that under normal conditions, at least half of the GlcCer used 
for GM3 synthesis passes through the ER. It would be delivered 
to the cytosolic ER surface by FAPP2, fl  ip across the ER, and 
would be concentrated into ER–Golgi transport vesicles. This lat-
eral concentration in the ER membrane may be very similar to 
the proposed formation of lipid rafts in the Golgi (van Meer, 
1993). Localization of the Drosophila GCS to the ER (Kohyama-
Koganeya et al., 2004) has the same implications. Also, GalCer, 
which is synthesized on the lumenal surface of the ER of some 
cell types, may contribute to such a mechanism. The occurrence 
of lipid rafts in the ER (defi  ned by detergent insolubility) has 
been reported for yeast (Bagnat et al., 2000) and mammalian 
cells, where they were GlcCer dependent (Smith et al., 2006). 
They were suggested to play a role in protein sorting and 
toxin retrotranslocation across the ER membrane, respectively. 
The effects of FAPP2 knockdown on sphingolipid-mediated 
events at the TGN and apical plasma membrane of MDCK cells 
(Vieira et al., 2005, 2006) may be caused by the inhibition by 
FAPP2 of the GlcCer fl  ux through the ER or by its inhibitory 
effect on complex GSL synthesis (Fig. 7 H).
Nearly all GlcCer that reached the cell surface followed 
the concanamycin-sensitive pathway (Fig. 6 C). Concanamycin 
did not inhibit transport across the ER–Golgi (Fig. 3), which sug-
gests that the GlcCer that enters the Golgi via the ER is converted 
to higher GLSs and does not reach the cell surface as GlcCer. 
Thus, no GlcCer would pass through the trans-Golgi lumen to 
the plasma membrane, in contrast to GalCer, which is not further 
glycosylated. This may explain why oligodendrocytes synthesize 
very little SGlcCer as compared with SGalCer (Fig. 7 D).JCB • VOLUME 179 • NUMBER 1 • 2007  112
Physiological functions of GlcCer
Apart from being the precursor for the complex GSLs and play-
ing a role in membrane organization as part of lipid rafts on 
the lumenal surface of cellular membranes, GlcCer may exert 
specifi  c functions at one other location that is unusual for GSLs, 
the cytosolic surface of the Golgi and the ER membrane. GlcCer is 
synthesized on the cytosolic surface of the Golgi, from where 
it does not simply disappear by translocation across the Golgi 
membrane. From independent work, we have suggested a func-
tion for GlcCer on the cytosolic surface of the Golgi in sorting 
membrane proteins to the melanosomes (Sprong et al., 2001), 
which we have now identifi  ed as a stimulation of the vacuolar 
proton pump (unpublished data). Relevant issues are the sided-
ness of GlcCer in the ER and the location and mechanism by 
which it fl  ops to the lumenal side of the membrane. In addi-
tion, the function of the recently discovered GlcCer degrading 
ER and cytosolic β-glucosidases (Yildiz et al., 2006; Boot 
et al., 2007; Hayashi et al., 2007), the absence of which results 
in raised GlcCer levels, remains to be resolved. The fact that the 
GCS occurs in most eukaryotes, even in 50% of all fungi (Saito 
et al., 2006), suggests that eukaryotes use GlcCer for basic 
functions that we are about to unravel, but it is likely that evolution 
has overlaid the basic principles by many levels of regulation. 
This may explain why these basic principles of GlcCer action 
have remained obscure to date.
Materials and methods
Materials
BSA, fraction V, and other chemicals were purchased from Sigma-Aldrich 
unless indicated otherwise and were used in the highest purity available. 
Silica TLC plates were obtained from Merck, organic solvents were 
  purchased from Riedel de Haën, and cell culture media, reagents, and 
FCS were obtained from PAA. Cell culture plastics were purchased from 
Costar. Tran[
35S]label (>37 TBq/mmol), [
35S]H2SO4 (74 MBq/mmol), 
D-[1-
14C]galactose (1.8 GBq/mmol), [U-
14C]palmitic acid (18 GBq/mmol), 
[9,10(n)-
3H]palmitic acid (1.5 TBq/mmol), and L-[3-
14C]serine (1.9 GBq/
mmol) were obtained from GE Healthcare and MP Biomedicals. Lipids and 
lipid standards were obtained from Avanti Polar Lipids, Inc. C6-NBD–fatty 
acid was purchased from Invitrogen. C6-NBD– and [
3H]palmitoyl-GlcCer 
were synthesized as described in supplemental Materials and methods 
(available at http://www.jcb.org/cgi/content/full/jcb.200704091/DC1). 
EST clones were purchased from RZPD. Rabbit antisera against the V5 and 
HA epitope (Y11) were obtained from Sigma-Aldrich and Santa Cruz Bio-
technology, Inc., respectively. The rabbit peptide antibody against mouse 
GLTP was a gift from K. Aikawa-Kojima (Ochanomizu University, Tokyo, 
Japan). The rabbit serum against GM130 was a gift from E. Sztul (University 
of Alabama, Birmingham, AL). Mouse anti-V5 antibody was purchased from 
Invitrogen, mouse mAb 16B12 anti-HA was obtained from BabCO, mouse 
anti-GM130 antibodies were obtained from BD Biosciences, and mouse 
anti–glyceraldehyde-3 phosphate dehydrogenase was purchased from 
Applied Biosystems. Fluorescent secondary goat antibodies were obtained 
from Jackson ImmunoResearch Laboratories, Inc. HRP-conjugated secondary 
goat anti–rabbit IgG was purchased from DakoCytomation. Recombinant GLTP 
was produced as described in supplemental Materials and methods.
DNA constructs
Plasmids are described in Table I. ORFs were ampliﬁ   ed by PCR using 
cDNA clones as a template. PCR products were gel puriﬁ  ed and cloned 
into mammalian expression vectors containing a sequence encoding for a 
triple HA tag (3*YPYDVPDYA) at the 5′ or 3′ end or a single HA or V5 tag 
(G  K  P  I  P  N  P  L  L  G  L  D  S  T  ) at the 3′ end. SGCS is a chimeric construct containing 
a triple HA tag, the rat PAPS transporter, a double myc tag as spacer 
(2*E  Q  K  L  I  S  E  E  D  L  ), and the mouse SGalCer synthase. Primers containing 
RNAi sequences of FAPP2 and lamin were inserted between the BglII 
and HindIII sides of the RNAi plasmid pKoen (Deneka et al., 2003). 
All synthetic constructs were veriﬁ  ed by restriction analysis and dye termi-
nation sequencing of both strands.
Cell culture, transfection, and RNAi
HeLa, CHO, and CHO-lec8 cells were purchased from American Type 
Culture Collection. D6P2T cells were a gift from S. Pfeiffer (University of 
Connecticut Medical School, Farmington, CT; Bansal and Pfeiffer, 1987). 
CHO-GalCS cells have been described previously (as CHO-CGalT; van 
der Bijl et al., 1996). MEB4 cells were purchased from the Institute of Physi-
cal and Chemical Research Cell Bank. The MF and TKO lines (Wijnholds 
et al., 2000; De Rosa et al., 2004) were obtained from P. Borst (Nether-
lands Cancer Institute, Amsterdam, Netherlands). MDCK strain II cells 
  infected with recombinant retroviruses carrying short hairpin RNA against 
FAPP2 have been described previously (Vieira et al., 2005). All cells were 
grown in DME, stable glutamine, 4.5 g/liter glucose, and 10% FCS at 
37°C with 5% CO2. Stable transfectants were grown in the presence of 
200 U/ml hygromycin B or 0.6 mg/ml geneticin (G418). Cells were trans-
fected using  1 μl LipofectAMINE 2000 and  0.3 μg DNA per squared 
centimeter of cells. For transient protein expression, the cells were used 
1 d after transfection. For the generation of stable transfectants, the cells 
were trypsinized 24 h after transfection and divided over four 15-cm 
dishes in culture medium containing hygromycin B or G418. Medium was 
refreshed weekly, and, after  3 wk, individual colonies were selected for 
green ﬂ  uorescence in the nucleus (Deneka et al., 2003) and trypsinized 
using a metal cylinder.
Quantitative IEM and confocal laser-scanning microscopy
Stably transfected HeLa cells were ﬁ  xed with 2% PFA + 0.2% glutaralde-
hyde in 0.1 M phosphate buffer, pH 7.4, and incubated for 4 h at room 
temperature followed by an overnight incubation at 4°C. After ﬁ  xation, 
cells were rinsed with PBS and with PBS containing 0.02 M glycine, 
scraped, and pelleted in 12% gelatin. Small blocks of the embedded cell 
pellets were inﬁ  ltrated overnight with 2.3 M sucrose, mounted on alumi-
num pins, and frozen in liquid nitrogen. Ultrathin cryosections were cut at 
–120°C, picked up with 1% methylcellulose and 1.2 M sucrose, thawed, 
and collected on grids. After washing with PBS containing 0.02 M glycine, 
sections were double labeled as described previously (Slot et al., 1991) 
with antibodies against the tags (mouse) and the cis-Golgi marker GM130 
(rabbit). For sub-Golgi localization of the tagged enzymes, immunogold 
particles were quantiﬁ  ed per cisterna. For each enzyme, 20 Golgi stacks 
were selected on double-labeled sections based on the following criteria: 
clear visibility of ﬁ  ve cisternae per Golgi, which we denoted as cisterna 
1–5 (Martinez-Menarguez et al., 2001), the presence of at least ﬁ  ve gold 
particles for the speciﬁ  c tag, and the presence of GM130 label as a cis-
Golgi reference. The cisterna containing the GM130 marker was located 
at one end of each Golgi stack and was denoted as cisterna 1. EM pictures 
of the selected Golgi stacks were made at a magniﬁ  cation of 30,000× or 
40,000×. The number of gold particles for the speciﬁ  c tag was counted 
per cisterna and expressed as a percentage of the total gold particles 
within that Golgi stack. The results for each enzyme are expressed as the 
mean percentage ± SEM (n = 20) of immunogold label for each cisterna. 
The reliability of the sample size was determined by accumulating data 
(for a given enzyme) until mean percentages remained stable within 10% of 
the end value for the last added ﬁ  ve Golgi stacks. 200–500 gold particles 
were localized for each protein. The signiﬁ  cance of the peak value of the 
gold particle percentage in a given cisterna was determined by performing 
paired t tests between cisternae with the lowest and highest percentage of 
gold label (P ≤ 0.05). Confocal laser-scanning microscopy was performed 
as described in supplemental Materials and methods.
Transport incubations on intact cells
24-well dishes with  2 × 10
5 MF, CHO-GalCS, or D6P2T cells were pre-
incubated with various drugs (1 μg/ml BFA, 5 μM PSC833, 50 μM glib-
enclamide, and 1 mM vanadate) for 0.5 h and metabolically labeled in the 
presence of inhibitors with radioactive precursors or C6-NBD–ceramide at 
37°C. For natural lipids and proteins, cells were labeled with 24 kBq/ml 
[1-
14C]palmitate, 15 kBq/ml [3-
14C]serine, 3,600 kBq/ml [
35S]H2SO4, or 
72 kBq/ml [
14C]galactose in culture medium for 1.5 h at 37°C and 5% 
CO2. Serine labeling was performed in MEMα because of its lower level 
of serine. The medium was replaced by HBSS with 20 mM Hepes, pH 7.4 
(HBSS’), containing puriﬁ  ed GLTP to extract GSLs from the cell surface at 
37°C. After varying times and GLTP concentrations (see Results; typically 
45 min with 1.5 mg/ml GLTP ± BFA), the medium was removed, and the 
cells were washed twice with 0.5 ml HBSS’. Wash buffers and medium 
were pooled and centrifuged for 5 min at 800 g to remove detached 
cells. The lipids were extracted from medium and cells as described in TRANSMEMBRANE TRANSLOCATION OF GLUCOSYLCERAMIDE • HALTER ET AL. 113
Lipid analysis. Transport is calculated as [
14C]- or [
35S]lipid in the medium 
as the percentage of the total amount of that lipid in medium plus cells. 
Effects of drugs or RNAi treatments on synthesis were determined by 
measuring the sphingolipid of interest against an internal standard like 
[
14C]phosphatidylserine in triplicate. For C6-NBD–GlcCer labeling, cells 
were incubated for 1 h with 1 μM C6-NBD–ceramide in HBSS’ + 1% BSA 
(wt/vol) to back-exchange newly synthesized C6-NBD–lipids appearing at 
the surface at 37°C. The buffer was replaced by HBSS’ + 1% BSA and 
incubated for 0.5 h on ice. The lipids were extracted from the combined 
label and washing buffers and from the cells as described in the Lipid 
analysis section. Transport is expressed as C6-NBD–lipid in the medium 
as the percentage of total C6-NBD–lipid. Measurements were performed 
in triplicate. For protein transport analysis, cells were incubated with 
800 kBq/ml [
35S]amino acids in culture medium for 135 min. Cells and media 
were analyzed as described in the SDS-PAGE and Western blotting section. 
Transport was calculated as the percentage of control.
Golgi translocation assay measuring [
3H]LacCer synthesis
15-cm
2 dishes with  1.5 × 10
7 HeLa cells were preincubated in the pres-
ence or absence of 1 μg/ml BFA in culture medium for 0.5 h at 37°C in 
5% CO2. Cells were then washed twice with PBS and scraped in homo  g-
enizing buffer (120 mM K
+-glutamate, 15 mM KCl, 5 mM NaCl, 0.8 mM 
CaCl2, 5 mM MnCl2, 2 mM MgCl2, 1.6 mM EGTA, 20 mM Hepes/KOH, 
pH 7.2, 1 μg/ml apoprotein, 1 μg/ml leupeptin, 1 μg/ml pepstatin, 5 μg/ml 
antipain, and 1 mM benzamidine). Cells were centrifuged at 300 g for 
5 min at 4°C, taken up in 800 μl of homogenizing buffer, and broken up 
by passing 10 times through a homogenizer (0.016 ball size; European 
Molecular Biology Laboratory). Nuclei and unbroken cells were removed 
from PNS by spinning for 10 min at 300 g at 4°C. Soluble GLTP–[
3H]GlcCer 
complexes were prepared as follows: 0.4 MBq [
3H]GlcCer in 10 μl ethanol 
were injected into 1,200 μl of homogenizing buffer containing 12 μg 
GLTP. The mix was incubated for 20 min at 37°C and spun down for 5 min 
at 20,000 g to remove aggregates. 100 μl PNS (0.25 mg/ml) was in-
cubated for 1 h at 37°C in the presence or absence of BFA, with 100 μl 
GLTP–[
3H]GlcCer complexes, 2 mM UDP-Gal, and 2 mM ATP in a volume 
of 500 μl. Lipids were extracted as described in the next section, and LacCer 
synthesis was measured as the percentage of control.
Lipid analysis
Lipids were extracted and applied to TLC plates, which, when used to sep-
arate GalCer from GlcCer, had been dipped in 2.5% wt/vol boric acid in 
MeOH and dried (all as described previously; van der Bijl et al., 1996). 
Lipids were generally separated by 2D TLC using in the ﬁ  rst dimension 
  either CHCl3/MeOH/25% vol/vol NH4OH/water (65:35:4:4 vol/vol) or 
CHCl3/MeOH/0.2% aqueous CaCl2 (55:45:10 vol/vol) with the acidic 
solvent CHCl3/MeOH/acetone/HAc/water (50:20:10:10:5 vol/vol) for 
the second dimension. C6-NBD–lipids were analyzed by 1D TLC in the 
acidic running solvent. 1D TLC plates of [
35S]H2SO4-labeled cells and of 
PNS were developed in the CaCl2 mixture. Radiolabeled spots were de-
tected by exposure of phosphorimaging screens and read-out on a Per-
sonal FX phosphorimager. TLC plates with ﬂ  uorescent lipids were directly 
developed using a phosphorimager (STORM 860; Molecular Dynamics). 
Spots were identiﬁ  ed by comparison with standards and quantiﬁ  ed using 
Quantity One software (Bio-Rad Laboratories).
SDS-PAGE and Western blotting
Cells were washed three times with PBS and were resuspended in protein 
sample buffer (200 mM Tris-HCl, pH 6.8, 3% wt/vol SDS, 12% vol/vol 
glycerol, 1 mM EDTA, 0.003% wt/vol bromophenol blue, and 50 mM 
DTT). Media were centrifuged at 3,000 g to remove cell debris, and one-
third volume of 4× protein sample buffer was added. Samples containing 
SGCS were incubated for 10 min at room temperature and for 0.5 h at 
50°C. All other samples were heated for 5 min at 95°C and resolved by 
SDS-PAGE on 7.5% minigels. Radioactive gels were dried and analyzed 
by ﬂ  uorography or a Personal FX phosphorimager (Bio-Rad Laboratories) 
using Quantity One software (Bio-Rad Laboratories). For Western blotting, 
nitrocellulose transfers were blocked for 1.5 h in PBS, 5% Protifar (Nutricia), 
and 0.2% Tween 20 (Blotto). Primary antibody incubations were performed 
for 1 h in Blotto. Detection was performed with HRP-conjugated secondary 
antibodies using enhanced chemiluminescence (GE Healthcare).
Online supplemental material
Fig. S1 shows that FAPP2 is localized in the perinuclear region of HeLa 
cells, where it partially colocalizes with the medial Golgi marker mannosi-
dase II, whereas GLTP distributes all over the cytosol except for the nucleus. 
Knocking down CERT resulted in an 80% reduction in the synthesis of SM 
and a 70% reduced synthesis of GlcCer and GM3, which is in line with a 
trans-Golgi location of a large fraction of GCS. Fig. S2 shows the puriﬁ  ed 
recombinant GLTP as a single band in a Coomassie-stained gel. The pro-
tein extracted C10-pyrene-GlcCer but not SM from membranes. Extraction 
of radiolabeled GlcCer from ﬁ  broblasts was concentration and time de-
pendent, whereas exogenous liposomes inhibited the extraction. Fig. S3 
shows that the product of the ER sulfotransferase construct SGCS was not 
SLacCer. Product synthesis was inhibited by the GCS inhibitor N-butylde-
oxygalactonojirimycin and by GCS knockdown but not by knocking down 
LCS. In addition, there was no reduced synthesis of the compound in Lec8 
cells, which synthesize far less LacCer because they lack the galactose im-
porter in their ER and Golgi. Fig. S4 shows that BFA does not inhibit GM3 
synthesis but does inhibit the synthesis of Gb3 in HeLa cells. Fig. S5 shows 
that BFA fully inhibited protein secretion in melanocytes but that FAPP2 
Table I. cDNAs and constructs used in this study
Protein Accession no. Plasmid Species Tag (N/C) Origin
CST NM006416 pCDNA3.1h Human HA (C) Ashikov et al., 2005
FAPP2 
GCS
NM032639 
NM003358
pCDNA3.1h 
pCDNA3.1h
Human 
Human
HA (C) 
HA3
b (C)
RZPD 
Sprong et al., 1998
GLTP
a NM175799 pCDNA3.1h Bovine HA (C) West et al., 2004
GLTP
a NM175799 pQE9 Bovine HIS6 (N) West et al., 2004
GM3S AF119416 pNHA3 Mouse HA3 (N) Giraudo and Maccioni, 2003
LCS AF097158 pNHA3 Mouse HA3 (N) Giraudo and Maccioni, 2003
NGT NM012243 pCDNA3.1 Human V5 (C) Ashikov et al., 2005
SGCS
c NM199111, 
NM016922
pNHA3 Rat, mouse HA3 (N) RZPD
SMS1
a NM147156 pCDNA3.1 Human V5 (C) Huitema et al., 2004
UGT
a NM005660 pMKIT-neo Human HA (C) Miura et al., 1996
MDR1
a NM000927 pRc/RSV Human NA van Helvoort et al., 1996
CERT NM023420 pKoen Mouse RNAi Synthetic
FAPP2 BC052360 pKoen Mouse RNAi Synthetic
GCS NM011673 pKoen Mouse RNAi Synthetic
Lamin NM001002011 pKoen Mouse RNAi Synthetic
LCS AF097158 pKoen Mouse RNAi Synthetic
NA, not applicable. GenBank/EMBL/DDBJ accession nos. are given in the second column.
aThe construction of this plasmid has been described previously (see Origin column).
bTriple HA tag.
cChimeric construct; see Materials and methods.JCB • VOLUME 179 • NUMBER 1 • 2007  114
knockdown had no effect on protein secretion. Supplemental Materials 
and methods provides information about the synthesis of sphingolipids con-
taining ﬂ  uorescent or radiolabeled fatty acids, the puriﬁ  cation of GLTP, and 
confocal laser-scanning microscopy. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200704091/DC1.
We are grateful to Kyoko Aikawa-Kojima, Hans Bakker, Hugo Maccioni, 
Monika Suchanek, Piet Borst, and Elizabeth Sztul for their generosity in provid-
ing reagents and for helpful discussions. We also thank René Scriwanek and 
Marc van Peski for excellent photographic work. We thank our colleagues for 
critical reading of the manuscript and for helpful discussions.
This work was supported by grant 902-23-197 from ZonMW with 
ﬁ  nancial support from the Netherlands Organization for Scientiﬁ  c Research, 
European Council (grant MRTN-CT-2004-5330 Flippases), Mizutani Foundation 
for Glycoscience (GvM), Academy of Finland, the Sigrid Jusélius and Magnus 
Ehrnrooth Foundations, Liv och Hälsa r.f., and Åbo Akademi University (grant 
to P. Mattjus).
Submitted: 17 April 2007
Accepted: 6 September 2007
Note added in proof. While a revised version of this manuscript was   under 
consideration, a related paper was published (D’Angelo, G., E. Polishchuk, 
G. Di Tullio, M. Santoro, A. Di Campli, A. Godi, G. West, J. Bielawski, 
C.C. Chuang, A.C. van der Spoel, et al. 2007. Nature. 449:62–67).
References
Allende, M.L., J. Li, D.S. Darling, C.A. Worth, and W.W. Young Jr. 2000. 
Evidence supporting a late Golgi location for lactosylceramide to gan-
glioside GM3 conversion. Glycobiology. 10:1025–1032.
Ashikov, A., F. Routier, J. Fuhlrott, Y. Helmus, M. Wild, R. Gerardy-Schahn, 
and H. Bakker. 2005. The human solute carrier gene SLC35B4 encodes 
a bifunctional nucleotide sugar transporter with specifi  city for UDP-xylose 
and UDP-N-acetylglucosamine. J. Biol. Chem. 280:27230–27235.
Bagnat, M., S. Keranen, A. Shevchenko, and K. Simons. 2000. Lipid rafts function 
in biosynthetic delivery of proteins to the cell surface in yeast. Proc. Natl. 
Acad. Sci. USA. 97:3254–3259.
Bansal, R., and S.E. Pfeiffer. 1987. Regulated galactolipid synthesis and cell surface 
expression in Schwann cell line D6P2T. J. Neurochem. 49:1902–1911.
Boot, R.G., M. Verhoek, W. Donker-Koopman, A. Strijland, J. van Marle, H.S. 
Overkleeft, T. Wennekes, and J.M. Aerts. 2007. Identifi   cation of the 
non-lysosomal glucosylceramidase as beta-glucosidase 2. J. Biol. Chem. 
282:1305–1312.
Bowman, B.J., M.E. McCall, R. Baertsch, and E.J. Bowman. 2006. A model for 
the proteolipid ring and bafi  lomycin/concanamycin-binding site in the vac-
uolar ATPase of Neurospora crassa. J. Biol. Chem. 281:31885–31893.
Burger, K.N., P. van der Bijl, and G. van Meer. 1996. Topology of sphingolipid 
galactosyltransferases in ER and Golgi: transbilayer movement of mono-
hexosyl sphingolipids is required for higher glycosphingolipid biosynthesis. 
J. Cell Biol. 133:15–28.
De Rosa, M.F., D. Sillence, C. Ackerley, and C. Lingwood. 2004. Role of multi-
ple drug resistance protein 1 in neutral but not acidic glycosphingolipid 
biosynthesis. J. Biol. Chem. 279:7867–7876.
Deneka, M., M. Neeft, I. Popa, M. van Oort, H. Sprong, V. Oorschot, J. Klumperman, 
P. Schu, and P. van der Sluijs. 2003. Rabaptin-5alpha/rabaptin-4 serves as 
a linker between rab4 and gamma(1)-adaptin in membrane recycling from 
endosomes. EMBO J. 22:2645–2657.
Farrer, R.G., M.P. Warden, and R.H. Quarles. 1995. Effects of brefeldin A on 
galactosphingolipid synthesis in an immortalized Schwann cell line: 
evidence for different intracellular locations of galactosylceramide sulfo-
transferase and ceramide galactosyltransferase activities. J. Neurochem. 
65:1865–1873.
Fugmann, T., A. Hausser, P. Schoffl  er, S. Schmid, K. Pfi  zenmaier, and M.A. 
Olayioye. 2007. Regulation of secretory transport by protein kinase 
D-mediated phosphorylation of the ceramide transfer protein. J. Cell Biol. 
178:15–22.
Futerman, A.H., and R.E. Pagano. 1991. Determination of the intracellular sites 
and topology of glucosylceramide synthesis in rat liver. Biochem. J. 
280:295–302.
Futerman, A.H., B. Stieger, A.L. Hubbard, and R.E. Pagano. 1990. Sphingomyelin 
synthesis in rat liver occurs predominantly at the cis and medial cisternae 
of the Golgi apparatus. J. Biol. Chem. 265:8650–8657.
Gasa, S., M.T. Casl, A. Makita, N. Sakakibara, T. Koyanagi, and T. Atsuta. 1990. 
Presence and characterization of glycolipid sulfotransferase in human 
cancer serum. Eur. J. Biochem. 189:301–306.
Giraudo, C.G., and H.J. Maccioni. 2003. Ganglioside glycosyltransferases orga-
nize in distinct multienzyme complexes in CHO-K1 cells. J. Biol. Chem. 
278:40262–40271.
Godi, A., A. Di Campli, A. Konstantakopoulos, G. Di Tullio, D.R. Alessi, G.S. 
Kular, T. Daniele, P. Marra, J.M. Lucocq, and M.A. De Matteis. 2004. 
FAPPs control Golgi-to-cell-surface membrane traffi  c by binding to ARF 
and PtdIns(4)P. Nat. Cell Biol. 6:393–404.
Hanada, K., K. Kumagai, S. Yasuda, Y. Miura, M. Kawano, M. Fukasawa, and 
M. Nishijima. 2003. Molecular machinery for non-vesicular traffi  cking of 
ceramide. Nature. 426:803–809.
Hayashi, Y., N. Okino, Y. Kakuta, T. Shiknai, M. Tani, H. Narimatsu, and M. Ito. 
2007. Klotho-related protein is a novel cytosolic neutral beta-glycosyl-
ceramidase. J. Biol. Chem. doi:10.1074/jbc.M700832200.
Holthuis, J.C., T. Pomorski, R.J. Raggers, H. Sprong, and G. van Meer. 2001. The 
organizing potential of sphingolipids in intracellular membrane transport. 
Physiol. Rev. 81:1689–1723.
Huitema, K., J. Van Den Dikkenberg, J.F. Brouwers, and J.C. Holthuis. 2004. 
Identifi  cation of a family of animal sphingomyelin synthases. EMBO J. 
23:33–44.
Jeckel, D., A. Karrenbauer, R. Birk, R.R. Schmidt, and F. Wieland. 1990. 
Sphingomyelin is synthesized in the cis Golgi. FEBS Lett. 261:155–157.
Jeckel, D., A. Karrenbauer, K.N. Burger, G. van Meer, and F. Wieland. 1992. 
Glucosylceramide is synthesized at the cytosolic surface of various Golgi 
subfractions. J. Cell Biol. 117:259–267.
Kohyama-Koganeya, A., T. Sasamura, E. Oshima, E. Suzuki, S. Nishihara, R. 
Ueda, and Y. Hirabayashi. 2004. Drosophila glucosylceramide synthase: 
a negative regulator of cell death mediated by proapoptotic factors. 
J. Biol. Chem. 279:35995–36002.
Kumagai, K., M. Kawano, F. Shinkai-Ouchi, M. Nishijima, and K. Hanada. 
2007. Interorganelle traffi  cking of ceramide is regulated by phosphory-
lation-dependent cooperativity between the PH and START domains of 
CERT. J. Biol. Chem. 282:17758–17766.
Lannert, H., C. Bunning, D. Jeckel, and F.T. Wieland. 1994. Lactosylceramide is 
synthesized in the lumen of the Golgi apparatus. FEBS Lett. 342:91–96.
Lannert, H., K. Gorgas, I. Meißner, F.T. Wieland, and D. Jeckel. 1998. Functional 
organization of the Golgi apparatus in glycosphingolipid biosynthesis. 
Lactosylceramide and subsequent glycosphingolipids are formed in the 
lumen of the late Golgi. J. Biol. Chem. 273:2939–2946.
Lefevre, C., S. Audebert, F. Jobard, B. Bouadjar, H. Lakhdar, O. Boughdene-
Stambouli, C. Blanchet-Bardon, R. Heilig, M. Foglio, J. Weissenbach, 
et al. 2003. Mutations in the transporter ABCA12 are associated with 
lamellar ichthyosis type 2. Hum. Mol. Genet. 12:2369–2378.
Levine, T., and C. Loewen. 2006. Inter-organelle membrane contact sites: through 
a glass, darkly. Curr. Opin. Cell Biol. 18:371–378.
Lippincott-Schwartz, J., L. Yuan, C. Tipper, M. Amherdt, L. Orci, and R.D. 
Klausner. 1991. Brefeldin A’s effects on endosomes, lysosomes, and the 
TGN suggest a general mechanism for regulating organelle structure and 
membrane traffi  c. Cell. 67:601–616.
Malinina, L., M.L. Malakhova, A. Teplov, R.E. Brown, and D.J. Patel. 2004. Structural 
basis for glycosphingolipid transfer specifi  city. Nature. 430:1048–1053.
Martinez-Menarguez, J.A., R. Prekeris, V.M. Oorschot, R. Scheller, J.W. Slot, 
H.J. Geuze, and J. Klumperman. 2001. Peri-Golgi vesicles contain retro-
grade but not anterograde proteins consistent with the cisternal progres-
sion model of intra-Golgi transport. J. Cell Biol. 155:1213–1224.
Miura, N., N. Ishida, M. Hoshino, M. Yamauchi, T. Hara, D. Ayusawa, and M. 
Kawakita. 1996. Human UDP-galactose translocator: molecular cloning 
of a complementary DNA that complements the genetic defect of a mu-
tant cell line defi  cient in UDP-galactose translocator. J. Biochem. (Tokyo). 
120:236–241.
Munro, S. 2003. Cell biology: earthworms and lipid couriers. Nature. 426:775–776.
Nakamura, N., C. Rabouille, R. Watson, T. Nilsson, N. Hui, P. Slusarewicz, T.E. 
Kreis, and G. Warren. 1995. Characterization of a cis-Golgi matrix protein, 
GM130. J. Cell Biol. 131:1715–1726.
Pagano, R.E., O.C. Martin, A.J. Schroit, and D.K. Struck. 1981. Formation of asym-
metric phospholipid membranes via spontaneous transfer of fl  uorescent lipid 
analogues between vesicle populations. Biochemistry. 20:4920–4927.
Papadopulos, A., S. Vehring, I. Lopez-Montero, L. Kutschenko, M. Stockl, P.F. 
Devaux, M. Kozlov, T. Pomorski, and A. Herrmann. 2007. Flippase activ-
ity detected with unlabeled lipids by shape changes of giant unilamellar 
vesicles. J. Biol. Chem. 282:15559–15568.
Perry, R.J., and N.D. Ridgway. 2006. Oxysterol-binding protein and vesicle-
associated membrane protein-associated protein are required for sterol-
dependent activation of the ceramide transport protein. Mol. Biol. Cell. 
17:2604–2616.
Pewzner-Jung, Y., S. Ben-Dor, and A.H. Futerman. 2006. When do Lasses 
(longevity assurance genes) become CerS (ceramide synthases)? Insights 
into the regulation of ceramide synthesis. J. Biol. Chem. 281:25001–25005.TRANSMEMBRANE TRANSLOCATION OF GLUCOSYLCERAMIDE • HALTER ET AL. 115
Rabouille, C., N. Hui, F. Hunte, R. Kieckbusch, E.G. Berger, G. Warren, and 
T. Nilsson. 1995. Mapping the distribution of Golgi enzymes involved in the 
construction of complex oligosaccharides. J. Cell Sci. 108:1617–1627.
Saito, K., N. Takakuwa, M. Ohnishi, and Y. Oda. 2006. Presence of glucosyl-
ceramide in yeast and its relation to alkali tolerance of yeast. Appl. 
Microbiol. Biotechnol. 71:515–521.
Slot, J.W., H.J. Geuze, S. Gigengack, G.E. Lienhard, and D.E. James. 1991. 
Immuno-localization of the insulin regulatable glucose transporter in 
brown adipose tissue of the rat. J. Cell Biol. 113:123–135.
Smith, D.C., D.J. Sillence, T. Falguieres, R.M. Jarvis, L. Johannes, J.M. Lord, 
F.M. Platt, and L.M. Roberts. 2006. The association of Shiga-like toxin 
with detergent-resistant membranes is modulated by glucosylceramide 
and is an essential requirement in the endoplasmic reticulum for a cyto-
toxic effect. Mol. Biol. Cell. 17:1375–1387.
Sprong, H., B. Kruithof, R. Leijendekker, J.W. Slot, G. van Meer, and P. van der 
Sluijs. 1998. UDP-galactose:ceramide galactosyltransferase is a class I 
integral membrane protein of the endoplasmic reticulum. J. Biol. Chem. 
273:25880–25888.
Sprong, H., S. Degroote, T. Claessens, J. van Drunen, V. Oorschot, B.H. 
Westerink, Y. Hirabayashi, J. Klumperman, P. van der Sluijs, and G. van 
Meer. 2001. Glycosphingolipids are required for sorting melanosomal 
proteins in the Golgi complex. J. Cell Biol. 155:369–380.
Sprong, H., S. Degroote, T. Nilsson, M. Kawakita, N. Ishida, P. van der Sluijs, and 
G. van Meer. 2003. Association of the Golgi UDP-galactose transporter 
with UDP-galactose:ceramide galactosyltransferase allows UDP-galactose 
import in the endoplasmic reticulum. Mol. Biol. Cell. 14:3482–3493.
Trinchera, M., B. Pirovano, and R. Ghidoni. 1990a. Sub-Golgi distribution in rat 
liver of CMP-NeuAc GM3- and CMP-NeuAc:GT1b alpha 2—-8sialyl-
transferases and comparison with the distribution of the other glycosyl-
transferase activities involved in ganglioside biosynthesis. J. Biol. Chem. 
265:18242–18247.
Trinchera, M., R. Ghidoni, S. Sonnino, and G. Tettamanti. 1990b. Recycling of 
glucosylceramide and sphingosine for the biosynthesis of gangliosides 
and sphingomyelin in rat liver. Biochem. J. 270:815–820.
van der Bijl, P., G.J. Strous, M. Lopes-Cardozo, J. Thomas-Oates, and G. van 
Meer. 1996. Synthesis of non-hydroxy-galactosylceramides and galactosyl-
diglycerides by hydroxy-ceramide galactosyltransferase. Biochem. J. 
317:589–597.
van Helvoort, A., A.J. Smith, H. Sprong, I. Fritzsche, A.H. Schinkel, P. Borst, 
and G. van Meer. 1996. MDR1 P-glycoprotein is a lipid translocase of 
broad specifi  city, while MDR3 P-glycoprotein specifi  cally translocates 
phosphatidylcholine. Cell. 87:507–517.
van Meer, G. 1993. Transport and sorting of membrane lipids. Curr. Opin. Cell 
Biol. 5:661–673.
van Meer, G., D. Halter, H. Sprong, P. Somerharju, and M.R. Egmond. 2006. 
ABC lipid transporters: extruders, fl  ippases, or fl  opless activators? FEBS 
Lett. 580:1171–1177.
Vieira, O.V., P. Verkade, A. Manninen, and K. Simons. 2005. FAPP2 is involved 
in the transport of apical cargo in polarized MDCK cells. J. Cell Biol. 
170:521–526.
Vieira, O.V., K. Gaus, P. Verkade, J. Fullekrug, W.L. Vaz, and K. Simons. 2006. 
FAPP2, cilium formation, and compartmentalization of the apical mem-
brane in polarized Madin-Darby canine kidney (MDCK) cells. Proc. 
Natl. Acad. Sci. USA. 103:18556–18561.
Wang, T.Y., and J.R. Silvius. 2000. Different sphingolipids show differential 
partitioning into sphingolipid/cholesterol-rich domains in lipid bilayers. 
Biophys. J. 79:1478–1489.
Warnock, D.E., M.S. Lutz, W.A. Blackburn, W.W. Young Jr., and J.U. Baenziger. 
1994. Transport of newly synthesized glucosylceramide to the plasma mem-
brane by a non-Golgi pathway. Proc. Natl. Acad. Sci. USA. 91:2708–2712.
Weisz, O.A. 2003. Acidifi  cation and protein traffi  c. Int. Rev. Cytol. 226:259–319.
West, G., Y. Nymalm, T.T. Airenne, H. Kidron, P. Mattjus, and T.T. Salminen. 
2004. Crystallization and X-ray analysis of bovine glycolipid transfer 
protein. Acta Crystallogr. D Biol. Crystallogr. 60:703–705.
Wijnholds, J., E.C. de Lange, G.L. Scheffer, D.J. van den Berg, C.A. Mol, M. van 
der Valk, A.H. Schinkel, R.J. Scheper, D.D. Breimer, and P. Borst. 2000. 
Multidrug resistance protein 1 protects the choroid plexus epithelium 
and contributes to the blood-cerebrospinal fl  uid barrier. J. Clin. Invest. 
105:279–285.
Yamaoka, S., M. Miyaji, T. Kitano, H. Umehara, and T. Okazaki. 2004. Expression 
cloning of a human cDNA restoring sphingomyelin synthesis and cell 
growth in sphingomyelin synthase-defective lymphoid cells. J. Biol. Chem. 
279:18688–18693.
Yildiz, Y., H. Matern, B. Thompson, J.C. Allegood, R.L. Warren, D.M. Ramirez, 
R.E. Hammer, F.K. Hamra, S. Matern, and D.W. Russell. 2006. Mutation 
of beta-glucosidase 2 causes glycolipid storage disease and impaired male 
fertility. J. Clin. Invest. 116:2985–2994.